|
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). |
| |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen |
| |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst) |
| |
|
Honoraria - Merck; Ono Pharmaceutical; Pfizer |
Consulting or Advisory Role - Janssen Oncology |
Research Funding - Ono Pharmaceutical; Sanofi |
| |
|
Leadership - Cancer clinic london Limited liability partnership |
Consulting or Advisory Role - Bayer; Gilead Sciences; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche |
Speakers' Bureau - Bristol Myers Squibb Foundation; Pfizer |
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst) |
Travel, Accommodations, Expenses - Nektar; Roche/Genentech |
| |
|
Stock and Other Ownership Interests - Arvinas; Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Macrogenics; Medtronic |
Honoraria - Exelixis; Janssen Oncology; Merck; Novartis; Pfizer |
Consulting or Advisory Role - Johnson & Johnson |
Speakers' Bureau - AstraZeneca; Exelixis |
Research Funding - Astellas Pharma; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Employment - Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
|
Stock and Other Ownership Interests - Janssen |
| |
|
|
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; IDEAYA Biosciences; Janssen; Loxo; Merck; Mirati Therapeutics; Nektar; Seagen; Taiho Oncology |
Research Funding - Basilea Pharmaceutical; Bristol-Myers Squibb; Janssen; Merck; Millennium; Mirati Therapeutics; Nektar |